Episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 2009;29:7841.S55 OnabotulinumtoxinA for migraine therapy Andrea Negro1,two ([email protected]) 1 Regional Referral Headache Centre, Sant’Andrea Hospital, Via di Grottarossa 1035-1039, 00191; 2Department of Clinical and Molecular Medicine, Sapienza University of Rome, Italy The Journal of Headache and Pain 2017, 18(Suppl 1):S55 Since 2010 the armamentarium of 3-Methylvaleric Acid manufacturer preventative drugs for chronic migraine (CM) has grow to be wider with the introduction of OnabotulinumtoxinA (Botox. The European Headache Federation recognized the value of OnabotulinumtoxinA suggesting that, just before labeling a patient as impacted by refractory CM, a appropriate therapy with this drug desires to become completed [1]. In the final years quite a few real-life prospective studies provided further proof in clinical setting of OnabotulinumtoxinA 155-195 U efficacy for the headache prophylaxis in CM difficult by medication overuse headache (MOH) [2]. Recently we published the results of a prospective study on the longterm (two years) efficacy and safety of a single dose of OnabotulinumtoxinA (155 or 195 U) in individuals with CM plus MOH had failed preceding preventative drugs and detoxification attempts [3]. Both the doses were helpful and equally secure, but 195 U was additional productive than 155 U in lowering headache days, migraine days, discomfort medication intake days and Headache Influence Test (HIT)-6 score. Much more,S56 Trigeminal autonomic cephalalgias (TACs) Ferdinando Maggioni ([email protected]) Headache Centre, Division of Neurosciences, University of Padua, Italy The Journal of Headache and Pain 2017, 18(Suppl 1):S56 Trigeminal autonomic cephalalgias (TACs) are a group of main headaches comprehending the following syndromes: episodic and chronic cluster headache (CH), episodic and chronic paroxysmal hemicrania (PH), short-lasting unilateral neuralgiform headache attacks, and hemicrania continua(HC) [1]. Their phenotypes are comparable and attack duration could be the key function distinguishing the very first three TACs. An correct diagnosis is essential for the reason that of their diverse response to treatment options. Among TACs, CH is most typical; on the other hand TACs are about at least one hundred instances much less typical than migraine. CH prevalence in adults is 1 and interests specially the male population. CH commonly occurs at the very same time in the day, from after to eight occasions each day, and in the identical period with the year. CH is featured by serious unilateral peri-orbital and or temporal pain lasting from 15 to 180 minutes if untreated, linked with a minimum of one particular autonomic symptom (conjunctival injection, lacrimation, nasal congestion, rhinorrhea, facial sweating, miosis, ptosis and eyelid edema). Trigger elements can include alcohol, volatile chemicals or perhaps a warm atmosphere (three). Acute therapy consists of the use of oxygen at a rate of 12-15Lmin for at the least 15 minutes and triptans. Controlled Cuminaldehyde Purity & Documentation trials have investigated the efficacy of subcutaneous sumatriptan, nasal sumatriptan, and nasal zolmitriptan. When a preventiveThe Journal of Headache and Discomfort 2017, 18(Suppl 1):Page 20 ofmedication is needed, verapamil is definitely the reference treatment. PH attack attributes are characterized by unilateral, usually stabbing, headaches, shorter and more frequent than in cluster headaches. PH is responsive to remedy with indomethacin. Indomethacin dosages ranges from 25 to 75 mg, three times a day. SUNCT.
